InsidersTradesSigma
Total declarations
Companies
▲ Purchases (10 ops.)
▼ Sales (87 ops.)
Insider track record
CEODisclosed buys
10
Disclosed sells
87
T+90 hit rate
60%
T+90 mean return
+20.9%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Troendle August J., Chief Executive Officer and Chairman of the Board. Insider active across 2 companies, notably Medpace Holdings, Inc.. Cumulatively, 100 reports have been logged. Breakdown: 10 buys · 87 sells. Total volume traded: €620.1m. History available since 15 June 2021. The latest transaction was disclosed on 25 August 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Troendle August J.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations100 total
673 shares@ US$620.38Common StockSEC:0001622058-26-000008:0
4,000 shares@ US$620.03Common StockSEC:0001622058-26-000008:1
13,995 shares@ US$624.450.050% mcap1.2% of flowCommon StockSEC:0000892251-26-000152:0
1,983 shares@ US$620.230.0071% mcap0.2% of flowCommon StockSEC:0000892251-26-000152:1
27,174 shares@ US$618.790.10% mcap2.3% of flowCommon StockSEC:0000892251-26-000125:1
15,609 shares@ US$606.470.058% mcap1.3% of flowCommon StockSEC:0000892251-26-000125:0
11,366 shares@ US$601.530.042% mcap1.0% of flowCommon StockSEC:0000892251-26-000114:0
458 shares@ US$600.390.0017% mcap0.0% of flowCommon StockSEC:0000892251-26-000114:1
5,534 shares@ US$601.530.020% mcap0.5% of flowCommon StockSEC:0001622058-26-000006:0
17,610 shares@ US$605.110.063% mcap1.6% of flowCommon StockSEC:0001622058-26-000006:1
3,728 shares@ US$600.850.014% mcap0.3% of flowCommon StockSEC:0001622058-26-000004:0
3,510 shares@ US$600.010.013% mcap0.3% of flowCommon StockSEC:0001622058-26-000004:1
668 shares@ US$590.690.1% of flowCommon StockSEC:0001622058-25-000023:0
23,178 shares@ US$593.252.1% of flowCommon StockSEC:0001622058-25-000021:0
41,331 shares@ US$606.883.9% of flowCommon StockSEC:0001622058-25-000019:0
59,025 shares@ US$607.785.8% of flowCommon StockSEC:0001622058-25-000017:0
6,830 shares@ US$598.490.7% of flowCommon StockSEC:0001622058-25-000015:0
7,191 shares@ US$590.840.7% of flowCommon StockSEC:0001622058-25-000013:0
14,747 shares@ US$595.261.5% of flowCommon StockSEC:0001622058-25-000011:0
5,312 shares@ US$603.230.6% of flowCommon StockSEC:0001622058-25-000009:0
36,196 shares@ US$475.903.0% of flowCommon StockSEC:0001622058-25-000006:0
620 shares@ US$475.000.1% of flowCommon StockSEC:0001622058-25-000004:0
48,487 shares@ US$451.694.0% of flowCommon StockSEC:0001668397-25-000097:0
37,417 shares@ US$54.740.4% of flowCommon StockSEC:0001668397-25-000033:0
3,987 shares@ US$395.220.3% of flowCommon StockSEC:0001668397-24-000121:0
25 of 100 declarations
About Troendle August J.
Troendle August J. is Chief Executive Officer and Chairman of the Board, with declared roles at Medpace Holdings, Inc. as CEO and at Coherus BioSciences, Inc. as Director. He has 88 filings in total, and across the sampled filings from 2016-02-11 to 2025-12-04, buys amount to EUR 80782132 and sells to EUR 483686303, with Cession as the modal transaction nature.
